HauserSLBar-OrAComiG, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med2017; 376(3): 221–234.
2.
GavoilleARollotFCaseyR, et al. Acute clinical events identified as relapses with stable magnetic resonance imaging in multiple sclerosis. JAMA Neurol2024; 81(8): 814.
3.
GavoilleADemuthSNourredineM, et al. Evaluating MRI-confirmed relapses as a novel primary endpoint in multiple sclerosis trials. medRxiv [Preprint]. DOI: 10.1101/2025.10.10.25337738.
4.
KriegerSBodhinathanKXuY, et al. MS relapse redefined: Distinguishing true relapses from pseudoexacerbations in the ULTIMATE I and II trials comparing ublituximab vs teriflunomide (P3-6.001). Neurology2024; 102(7 Suppl. 1): 6567.
